Alumis Inc. (ALMS): Total Assets
$411.94M
As of 2025-12-31
$560.62M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $411.94M | +20.8% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $340.99M | +280.5% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $89.61M | n/a | 2025-03-19, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $42.21M | +31.1% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $25.65M | -52.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $59.03M | -34.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $20.27M | -14.8% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $29.92M | -16.5% |
Compare ALMS, TRDA, NAMS, CELU side by side · Screen every company in Pharmaceutical Preparations ↗